Rapport Therapeutics, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $0Mn |
Net Profits | $-56.62Mn |
Net Profit Margins | -Inf% |
Rapport Therapeutics, Inc. Common Stock’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2026. On a quarterly growth basis, Rapport Therapeutics, Inc. Common Stock has generated -100% fall in its revenue since last 3-months.
Rapport Therapeutics, Inc. Common Stock’s net profit fell -111.79% since last year same period to $-56.62Mn in the Q2 2026. On a quarterly growth basis, Rapport Therapeutics, Inc. Common Stock has generated -185.11% fall in its net profits since last 3-months.
Rapport Therapeutics, Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2026. On a quarterly growth basis, Rapport Therapeutics, Inc. Common Stock has generated -Inf% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -1.21 |
EPS Estimate Current Year | -1.21 |
Rapport Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -1.21 - a -30.11% fall from last quarter’s estimates.
Rapport Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -1.21.
Key Ratios
Earning Per Share (EPS) | -1.19 |
Rapport Therapeutics, Inc. Common Stock’s earning per share (EPS) fell -58.67% since last year same period to -1.19 in the Q2 2026. This indicates that the Rapport Therapeutics, Inc. Common Stock has generated -58.67% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-05-07 | -0.71 | -0.42 | 40.85% |
2026-08-05 | -0.93 | -1.19 | -27.96% |
